Memo Therapeutics
CHWho owns Memo Therapeutics?
Memo Therapeutics was owned by Ysios Capital Partners through Ysios BioFund III (2020 vintage) from 2024 to 2026, exited via Trade Sale. Across its history, Memo Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.
Buyer identity available on Pro.
Hand-verified · updated 2026-08-03
Key facts
- ·Fully exited in 2026.
- ·Average hold across 2 realized cycles: 5 years.
Ownership history
2 ownership periods · co-invest detected
More from Ysios BioFund III
Other portfolio companies in the same fund.
US
More PE-backed in Biotech
Comparable biotech deals from other GPs.
Save this record to your watchlist and pick up your research where you left off. No spam.
Who could buy Memo Therapeutics?
7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.
Find likely buyersGet the full record on Memo Therapeutics.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in